Alpha 2.0
Login Register
» Authors » A Beeker

A Beeker

Explore the profile of A Beeker including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 122
Followers 0
Related Specialties
Oncology
General Medicine
Hematology
Top 10 Co-Authors
M Westerman
O de Weerdt
M Hoogendoorn
A W G van der Velden
A M T van der Velden
A Meerveld-Eggink
M R Nijziel
D H Biesma
G T Rijkers
M B L Leys
Published In
Neth J Med
Eur J Cancer
Ann Oncol
Leuk Res
Breast Cancer Res Treat
Affiliations
Soon will be listed here.
Recent Articles
1.
Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial
Seefat M, Stege C, Lissenberg-Witte B, Levin M, Timmers G, Hoogendoorn M, et al.
Eur J Cancer . 2024 Jun; 207:114153. PMID: 38870747
Background: Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality of life (HRQoL). Currently, data on changes in HRQoL of frail and...
2.
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer
de Boo L, Jozwiak K, Ter Hoeve N, van Diest P, Opdam M, Wang Y, et al.
ESMO Open . 2024 Mar; 9(3):102923. PMID: 38452438
Background: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment...
3.
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
van de Loosdrecht A, Cremers E, Alhan C, Duetz C, In t Hout F, Visser-Wisselaar H, et al.
Leukemia . 2024 Jan; 38(4):840-850. PMID: 38297135
A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients...
4.
Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy
van der Zande K, Tutuhatunewa-Louhanepessy R, Hamberg P, Ras S, de Feijter J, Dezentje V, et al.
Clin Genitourin Cancer . 2024 Jan; 22(2):445-453.e1. PMID: 38246830
Background: There is new interest in platinum-based treatment of patients with metastatic castration resistant prostate cancer (mCRPC), to which a subgroup responds. Although platinum sensitivity is suggested to be associated...
5.
Treatment sequences and drug costs from diagnosis to death in multiple myeloma
Seefat M, Cucchi D, Groen K, Donker M, van der Hem K, Westerman M, et al.
Eur J Haematol . 2023 Oct; 112(3):360-366. PMID: 37821211
Novel therapies for multiple myeloma (MM) have improved patient survival, but their high costs strain healthcare budgets. End-of-life phases of treatment are generally the most expensive, however, these high costs...
6.
The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies
de Joode K, van de Geer W, van Leenders G, Hamberg P, Westgeest H, Beeker A, et al.
Sci Rep . 2023 Jul; 13(1):10720. PMID: 37400554
Differences in the clinical course and treatment responses in individual patients with advanced renal cell carcinoma (RCC) can largely be explained by the different genomics of this disease. To improve...
7.
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
Opdam M, van der Noort V, Kleijn M, Glas A, Mandjes I, Kleiterp S, et al.
Breast Cancer Res Treat . 2022 May; 194(2):265-278. PMID: 35587322
Purpose: Guidelines recommend endocrine treatment for estrogen receptor-positive (ER+) breast cancers for up to 10 years. Earlier data suggest that the 70-gene signature (MammaPrint) has potential to select patients that...
8.
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study
van der Meulen M, Bakunina K, Nijland M, Minnema M, Cull G, Stevens W, et al.
Ann Oncol . 2020 May; 31(8):1046-1055. PMID: 32371123
Background: The impact of rituximab on health-related quality of life (HRQoL) in primary central nervous system lymphoma patients is not well known. We determined the impact of rituximab added to...
9.
The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial
van der Werf A, Langius J, Beeker A, Ten Tije A, Vulink A, Haringhuizen A, et al.
Clin Nutr . 2020 Feb; 39(10):3005-3013. PMID: 32037284
Background & Aims: A low muscle mass before start of treatment and loss of muscle mass during chemotherapy is related to adverse outcomes in patients with cancer. In this randomized...
10.
Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study
van Gelder M, van Oers M, Alemayehu W, Abrahamse-Testroote M, Cornelissen J, Chamuleau M, et al.
Bone Marrow Transplant . 2016 Feb; 51(6):799-806. PMID: 26878656
Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We...